Big the vote of confidence from the Professor, and what a bargain entry position for him.
The Candor acquisition makes sense in that we capture more of the market while also re-establishing a trusted connection with patients - which was sorely neglected under the previous, unmentionable one.
The industry in Australia is consolidating fast, with margins compressing because of the increased competition, but it is good to Robert Iervasi and the team getting us back on track.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.69M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 63702 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 6000 | 1 |
View Market Depth
| Last trade - 09.59am 01/08/2025 (20 minute delay) ? |
| VIT (ASX) Chart |
Day chart unavailable